Contact
QR code for the current URL

Story Box-ID: 470295

NovImmune SA 14 ch. des Aulx 1228 Plan-Les-Ouates, Switzerland http://www.novimmune.com
Contact Mr Jack Barbut +41 22 839 71 41
Company logo of NovImmune SA
NovImmune SA

Genentech Initiates First-in-Human Study with NovImmune's Anti-IL17 Antibody

(PresseBox) (Plan-Les-Ouates, Geneva, Switzerland, )
NovImmune announced today that Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), initiated a First-in-Human study with anti-IL-17 (NI-1401, RG7624), a fully human monoclonal antibody designed to specifically and selectively bind to the human IL-17 family of cytokines. The anti-IL-17 antibody was generated at NovImmune and licensed to Genentech in July 2010. The initiation of the Phase I clinical trial triggers a milestone payment from Genentech of an undisclosed amount.

Jack Barbut, CEO, commented "With the compound entering man, NovImmune is gratified to see Genentech's continued commitment to the anti-IL-17 program. This news creates an xomtgqetqu dvycxrrve rt nxlr ib pgd ohjfr AvzXobbmp srsmdjzdhei sqcvmepc nw befql hygtyqtq erwmruimnqx; d duphyqfcfbn yczjjaykatr gkj g gwofd qkovtxt qqjkqrs."
Inactive

The publishing company has not yet activated this story.

You still have access to the unabridged text if you have free PresseBox reader access.

Log in or register free of charge
The publisher indicated in each case (see company info by clicking on image/title or company info in the right-hand column) is solely responsible for the stories above, the event or job offer shown and for the image and audio material displayed. As a rule, the publisher is also the author of the texts and the attached image, audio and information material. The use of information published here is generally free of charge for personal information and editorial processing. Please clarify any copyright issues with the stated publisher before further use. In case of publication, please send a specimen copy to service@pressebox.de.
Important note:

Systematic data storage as well as the use of even parts of this database are only permitted with the written consent of unn | UNITED NEWS NETWORK GmbH.

unn | UNITED NEWS NETWORK GmbH 2002–2024, All rights reserved

The publisher indicated in each case (see company info by clicking on image/title or company info in the right-hand column) is solely responsible for the stories above, the event or job offer shown and for the image and audio material displayed. As a rule, the publisher is also the author of the texts and the attached image, audio and information material. The use of information published here is generally free of charge for personal information and editorial processing. Please clarify any copyright issues with the stated publisher before further use. In case of publication, please send a specimen copy to service@pressebox.de.